Actinium Pharmaceuticals, Inc.
AMEX:ATNMBiotechnology
+$0.22 today
- Market cap
- $51.56M
- Beta
- 0.02
- P/E (TTM)
- 4.4
- EPS (TTM)
- $0.36
Volume 0.18M
Average 0.15M
ATNM Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Actinium Pharmaceuticals, Inc.AMEX: ATNM
Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026
Stock-based compensation declines year over year
Q2 FY2026 stock-based compensation of $118K fell 40.1% year over year, ahead of the -98.0% change in trailing-twelve-month stock-based compensation. Over 3 fiscal years it compounded at +48.7% a year.
Context
- Stock-based compensation amounted to 10211.1% of revenue in FY2025.
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -40.1% holds above the trailing-twelve-month pace of -98.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 9.19M USD
- Year-over-year change
- +73.7%
- 4-year CAGR
- +52.6%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.19M | +73.7% |
| FY2024 | 2024-12-31 | 5.29M | +37.7% |
| FY2023 | 2023-12-31 | 3.84M | +37.5% |
| FY2022 | 2022-12-31 | 2.8M | +65.0% |
| FY2021 | 2021-12-31 | 1.69M | — |
Stock-Based Compensation vs competitors
How ATNM compares with its peers on the latest reported figures
- ATNM's LTM Jun 2026 stock-based compensation of $237K is the smallest of the 5 companies compared; the peer median is $3.99M.
- Its year-over-year change of -98.0% is the 4th highest of 5, against a peer median of -28.5%.
- Stock-based compensation amounts to 0.7% of revenue for ATNM, versus a peer median of 12.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $1.79B | -27809.6% | +824.6% | — | |
OKUROnKure Therapeutics, Inc. | LTM Mar 2026 | $11.67M | +86.0% | +523.5% | — |
| LTM Mar 2026 | $6.49M | +5.8% | -6.3% | 12.1% | |
| LTM Mar 2026 | $1.48M | -62.7% | +481.3% | — | |
| LTM Jun 2026 | $237K | -98.0% | +48.7% | 0.7% | |
| Peer median (excluding ATNM) | $3.99M | -28.5% | +502.4% | 12.1% | |
Competitors are the stored peer set for ATNM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (24.77M) | (33.02M) | (48.82M) | (38.24M) | (33.89M) |
| Depreciation & Amortization | 524K | 699K | 790K | 811K | 821K |
| Deferred Income Tax | (1.55M) | 402K | 0 | 0 | 0 |
| Stock-Based Compensation | 1.69M | 2.8M | 3.84M | 5.29M | 9.19M |
| Change in Working Capital | 1.69M | 38.17M | (3.15M) | (932K) | (704K) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.2M | 4.6M | (2.18M) | (387K) | (346K) |
| Other Working Capital | 495K | 33.57M | (972K) | (545K) | (358K) |
| Other Non-Cash Items | 1.55M | (402K) | 0 | 0 | 0 |
| Operating Cash Flow | (20.87M) | 8.64M | (47.34M) | (33.07M) | (24.58M) |
| Capital Expenditures | (133K) | (366K) | (153K) | (11K) | (104K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (133K) | (366K) | (153K) | (11K) | (104K) |
| Debt Repayment | (85K) | (49K) | (4K) | (9K) | (10K) |
| Common Stock Issued | 35.3M | 23.16M | 14.87M | 29.26M | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (207K) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 6K | 0 | 0 | 75K | 0 |
| Financing Cash Flow | 35.22M | 23.11M | 14.87M | 29.32M | (217K) |
| Effect of Forex Changes | 0 | 0 | (11K) | 0 | 6K |
| Net Change in Cash | 14.22M | 31.39M | (32.63M) | (3.76M) | (24.9M) |
| Free Cash Flow | (21M) | 8.28M | (47.49M) | (33.08M) | (24.68M) |
Actinium Pharmaceuticals, Inc.
AMEX:ATNM
Intrinsic Alpha fair value
Locked
Current Price
$1.64
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.